Effect of Oral Sodium Bicarbonate Supplementation on urine TGF-beta in normal serum bicarbonate CKD, A randomized control trial.
Phase 3
Completed
- Conditions
- on-diabetic chronic kidney disease with subclinical metabolic acidosisBicarbonate, urine TGF-beta, urine ammonium, chronic kidney disease
- Registration Number
- TCTR20240817007
- Lead Sponsor
- Department of Medicine, Phramongkutklao Hospital and College of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 64
Inclusion Criteria
1.Age > 18 years old
2.Non-diabetic CKD stage 3-4
3.Normal serum bicarbonate
(HCO3 22-26 mEq/L)
Exclusion Criteria
1.Use of chronic daily oral alkali (such as sodium bicarbonate, sodium citrate, potassium citrate, etc)
2.Serum potassium < 3.3 or > 5.5 mEq/L
3.Self-reported vegetarian
4.New York Heart Association Class 3 or 4 heart failure symptom
5.History of staghorn calculi
6.Active glomerular disease requiring immunosuppressive agents
7.Kidney transplant patient
8.Pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method change of urinary TGF-beta at 12 weeks after treatment pg/ml
- Secondary Outcome Measures
Name Time Method ACR at 12 weeks after treatment mg/g,Serum HCO3 at 12 weeks after treatment mEq/L,Urine pH at 12 weeks after treatment -,Blood pressure at 12 weeks after treatment mmHg,Body weight at 12 weeks after treatment kg